Pulmonary hypertension as a result of drug therapy.
Pulmonary hypertension, as a result of adverse drug reactions, must be considered as a rare occurrence. With good medicinal chemistry and screening of compounds before entry into man, it should be almost totally avoidable. Life and medicine are a continuing challenge as our exploration of the regions of unknown biology throw up new targets and new mechanisms and may catch us again as the anorectic (anorectic) drug caught our predecessors.
Higenbottam
Tim
T
Division of Clinical Science (South), Medical School, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2RX, UK. tim.higenbottam@astrazeneca.com
Laude
Liz
L
Emery
Celia
C
Essener
Mohamed
M
D001067:Appetite Depressants / Q000009:adverse effects; D020372:Dexfenfluramine / Q000009:adverse effects; D016603:Eosinophilia-Myalgia Syndrome / Q000139:chemically induced; D005277:Fenfluramine / Q000009:adverse effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000503:physiopathology; D007049:Iatrogenic Disease; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects
D001067:Appetite Depressants; D020372:Dexfenfluramine; D005277:Fenfluramine; D017367:Selective Serotonin Reuptake Inhibitors